Actieve functies van Phil Baran
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Elsie Biotechnologies Inc.
 Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Directeur/Bestuurslid | 01-01-2021 | - |
| Oprichter | 01-01-2021 | - |
Loopbaan van Phil Baran
Statistieken
Internationaal
| Verenigde Staten | 2 |
Operationeel
| Director/Board Member | 1 |
| Founder | 1 |
Sectoraal
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Health Technology |
- Beurs
- Insiders
- Phil Baran
- Ervaring
